Startups
Proteins by Design
Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life.
Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners.
Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life.
Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners.
Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
Overview
Location
United States, California, Monrovia
Employees
201-500
Total raised
$145M
Founded date
1997
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Feb 5, 2019 | Funding round | $120M |
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 22, 2024 | Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health | Terray Therapeutics, a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced Series B fu... |
| Jun 21, 2024 | Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform | BEIJING, June 21, 2024 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully ... |
| May 14, 2024 | Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies | DURHAM, N.C. and BEIJING, May 14, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across... |
| Sep 12, 2022 | Six New Member Companies Join the International Consortium for Innovation and Quality in Pharmaceutical Development | IQ continues to grow as an organization and advance key industry initiatives while delivering innovative approaches and effective therapies to patients. We look forward to mutually beneficial collaboration and progress of our portfolio to e... |
| Aug 5, 2021 | Xencor : Reports Second Quarter 2021 Financial Results (Form 8-K) | Xencor Reports Second Quarter 2021 Financial Results -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--August 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing enginee... |
| Jun 14, 2021 | INMUNE BIO, INC. INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution | INmune Bio, Inc. announced that the company has entered into a new $15 million credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund th... |
| Jun 14, 2021 | INMUNE BIO, INC. INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution | Purchase of Xencor Option potentially eliminates approximately 2.1 million shares of INmune future common stock dilution upon execution. LA JOLLA, Calif, June 14, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), ... |
| Mar 26, 2020 | What it’s like to go into the lab at a biopharma company during the coronavirus pandemic | Like grocery store clerks and Amazon delivery drivers, they’re among the essential workers of the coronavirus pandemic: the biopharma employees who must still go in to the lab or the manufacturing plant. But for these employees, going to wo... |
| Feb 5, 2019 | Xencor Receives $120M From Genentech | Monrovia-based biopharmaceuticals technology developer Xencor has received $120M in an upfront payment from Genentech this morning--and up to another $180M in development milestones--as part of a new deal to commercialize an immune activati... |
Show more
Reviews 0
FAQ about Xencor
When was Xencor founded?
Xencor was founded in 1997.
How much funding has Xencor raised?
Xencor has raised $145M in total across 2 funding rounds.
What funding rounds has Xencor raised?
Parsers VC lists 2 funding rounds of Xencor, among them a funding round of $120M on Feb 5, 2019.
What has the press written about Xencor?
Parsers VC has collected 16 articles mentioning Xencor, among them “Terray Therapeutics: $120 Million (Series B) Secured To Improve Human Health” (Oct 22, 2024) and “Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform” (Jun 21, 2024).
Is Xencor still active?
Yes, Xencor is active; its latest activity on Parsers VC dates from Aug 2, 2026.